168 related articles for article (PubMed ID: 8435988)
1. Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy.
Wing JR; Panz VR; Joffe BI; Seftel HC
Diabet Med; 1993; 10(1):50-5. PubMed ID: 8435988
[TBL] [Abstract][Full Text] [Related]
2. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
[TBL] [Abstract][Full Text] [Related]
3. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
Vestergaard H; Lund S; Bjørbaek C; Pedersen O
Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
[TBL] [Abstract][Full Text] [Related]
4. Insulin-receptor activity in nondiabetic and diabetic urbanized South African black women.
Panz VR; Joffe BI; Wing JR; Raal FJ; Seftel HC
Diabetes Care; 1992 Feb; 15(2):277-81. PubMed ID: 1547686
[TBL] [Abstract][Full Text] [Related]
5. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
Della Casa L; del Rio G; Glaser B; Cerasi E
Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
[TBL] [Abstract][Full Text] [Related]
6. Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Bianchi R; Bongers V; Bravenboer B; Erkelens DW
Diabetes Metab Rev; 1993 Nov; 9 Suppl 1():29S-34S. PubMed ID: 8299486
[TBL] [Abstract][Full Text] [Related]
7. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Poulsen MK; Henriksen JE; Hother-Nielsen O; Beck-Nielsen H
Diabetes Care; 2003 Dec; 26(12):3273-9. PubMed ID: 14633813
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus.
Mannucci E; Ognibene A; Cremasco F; Bardini G; Mencucci A; Pierazzuoli E; Ciani S; Fanelli A; Messeri G; Rotella CM
Diabet Med; 2000 Oct; 17(10):713-9. PubMed ID: 11110504
[TBL] [Abstract][Full Text] [Related]
9. Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects.
Ward G; Harrison LC; Proietto J; Aitken P; Nankervis A
Diabetes; 1985 Mar; 34(3):241-5. PubMed ID: 3882491
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
11. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises.
Umpierrez GE; Clark WS; Steen MT
Diabetes Care; 1997 Apr; 20(4):479-83. PubMed ID: 9096964
[TBL] [Abstract][Full Text] [Related]
14. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance, but normal basal rates of glucose production in patients with newly diagnosed mild diabetes mellitus.
Hother-Nielsen O; Beck-Nielsen H
Acta Endocrinol (Copenh); 1991 Jun; 124(6):637-45. PubMed ID: 2068893
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of acute and chronic hypoglycemic action of gliclazide.
da Tos V; Maran A; Vigili de Kreutzenberg S; Marchetto S; Tadiotto F; Bettio M; Marescotti MC; Tiengo A; Del Prato S
Acta Diabetol; 2000; 37(4):201-6. PubMed ID: 11450504
[TBL] [Abstract][Full Text] [Related]
17. In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment.
Bak JF; Møller N; Schmitz O; Saaek A; Pedersen O
Diabetologia; 1992 Aug; 35(8):777-84. PubMed ID: 1511806
[TBL] [Abstract][Full Text] [Related]
18. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.
Simpson HC; Sturley R; Stirling CA; Reckless JP
Diabet Med; 1990 Feb; 7(2):143-7. PubMed ID: 2137755
[TBL] [Abstract][Full Text] [Related]
19. Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Wajchenberg BL; Santomauro AT; Porrelli RN
Diabetes Res Clin Pract; 1993 May; 20(2):147-54. PubMed ID: 8375268
[TBL] [Abstract][Full Text] [Related]
20. Genetic cause of hyperglycaemia and response to treatment in diabetes.
Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
